Related references
Note: Only part of the references are listed.Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Karen A. Hicks et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
Comparison of 2-year clinical outcomes between diabetic versus nondiabetic patients with acute myocardial infarction after 1-month stabilization: Analysis of the prospective registry of DIAMOND (DIabetic acute myocardial infarctiON Disease) in Korea: an observational registry study
Seung-Ho Hur et al.
MEDICINE (2016)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
Jennifer B. Green et al.
AMERICAN HEART JOURNAL (2013)
Share Paper
